Compare Summit Therapeutics Inc (SMMT) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Summit Therapeutics Inc trades at $17.53 (market cap $13.71B), while NEOS S&P 500 High Income ETF trades at $54.1 (market cap $12.50B). The key difference: Summit Therapeutics Inc and NEOS S&P 500 High Income ETF are close in size by market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| SMMT | SPYI | |
|---|---|---|
Market Cap | $13.71B | $12.50B |
Volume | 6,173,057 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.38 | $54.42 |
52-Week Low | $12.43 | $47.98 |
Typical Hold Time | 16 Days | 58 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
SPYI trades at $54.095 with a modest 0.16% daily gain, showing bullish technical momentum with strong moving average signals. The ETF maintains consistent monthly dividend distributions around $0.53-0.54 per share, targeting income-focused investors. Recent news highlights SPYI's popularity among retirement portfolios while raising concerns about principal erosion from covered call strategies.
The outlook remains mixed - strong technicals and high yield appeal support near-term stability, but long-term capital preservation risks from the covered call strategy warrant caution. Income investors benefit from consistent distributions, though growth-oriented investors may find the strategy limiting during bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
